FDA extends action date of biologics licence application (BLA) for CAR-T drug lisocabtagene maraleucel (liso-cel) to end of 2020

This CD19-directed chimeric antigen receptor (CAR) T cell therapy is a treatment for adults with relapsed/refractory large B-cell lymphoma after at least two prior therapies. Bristol Myers Squibb submitted additional information which will require more time for the FDA to review.


Biospace Inc.